Anti-inflammatory capacity of lactobacilli peptidoglycan: Mucosal and systemic routes of administration promote similar effects - The authors' reply

Gut

Volumn 61, Issue 5, 2012, Pages 784-

  Grangette, Corinne ^a   Macho Fernandez, Elise ^a   Pot, Bruno ^a  

^a INSTITUT PASTEUR DE LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD103 ANTIGEN; INTERLEUKIN 10; PEPTIDOGLYCAN; PROBIOTIC AGENT; TRANSCRIPTION FACTOR FOXP3;

ADOPTIVE TRANSFER; ANTIINFLAMMATORY ACTIVITY; BACTERIAL STRAIN; COLITIS; DENDRITIC CELL; LACTOBACILLUS; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS SALIVARIUS; LETTER; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; STRAIN DIFFERENCE;

EID: 84859621627     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2011-301194     Document Type: Letter

References (4)

1. Matuchansky C. Anti-inflammatory lactobacilli: strain specificity. Gut 2012;61:786.
2. Macho Fernandez E, Valenti V, Rockel C, et al. Anti-inflammatory capacity of selected lactobacilli in experimental colitis is driven by NOD2-mediated recognition of a specific peptidoglycan-derived muropeptide. Gut 2011;60:1050-9.
3. Foligne B, Grangette C, Pot B. Probiotics in IBD: mucosal and systemic routes of administration may promote similar effects. Gut 2005;54:727-8. (Pubitemid 40559263)
4. Foligne B, Zoumpopoulou G, Dewulf J, et al. A key role of dendritic cells in probiotic functionality. PLoS ONE 2007;2:e313.